Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02726581 | An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma(CheckMate 602) | completed | Phase 3 | 170 | Bristol-Myers SquibbINDUSTRY | 16 | Mar 27, 2023 | clinicaltrials |
| NCT00385606 | Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC | completed | Phase 2 / Phase 3 | 400 | National Cancer Institute, NaplesOTHER | 1 |
| Mar 23, 2023 |
| clinicaltrials |
| NCT00199043 | Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma | completed | Phase 3 | 80 | Goethe UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT02634294 | Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT | completed | Phase 2 / Phase 3 | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT02942173 | CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT | completed | Phase 2 / Phase 3 | 150 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT01763671 | Paclitaxel-bevacizumab in Advanced Lung Cancer(Ultimate) | completed | Phase 3 | 166 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT01850303 | Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer(MODEL) | completed | Phase 3 | 632 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT00651456 | Mesothelioma Avastin Plus Pemetrexed-cisplatin Study(MAPS) | completed | Phase 2 / Phase 3 | 448 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT02564263 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | completed | Phase 3 | 628 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 13, 2023 | clinicaltrials |
| NCT00354120 | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant(GLOBAL) | completed | Phase 2 / Phase 3 | 121 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT01191957 | Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML(GITMO-AMLR2) | completed | Phase 3 | 252 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 2 | Mar 10, 2023 | clinicaltrials |
| NCT02345850 | Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) | completed | Phase 3 | 346 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 7, 2023 | clinicaltrials |
| NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | completed | Phase 3 | 541 | Bristol-Myers SquibbINDUSTRY | 26 | Mar 2, 2023 | clinicaltrials |
| NCT03351361 | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients(eNERGY) | completed | Phase 3 | 217 | Rennes University HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03150875 | A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC | completed | Phase 3 | 290 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT01090089 | Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma(DSM XIII) | completed | Phase 3 | 348 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT01938001 | Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)(AUGMENT) | completed | Phase 3 | 358 | CelgeneINDUSTRY | 17 | Feb 22, 2023 | clinicaltrials |
| NCT01721876 | Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) | completed | Phase 3 | 666 | Boehringer IngelheimINDUSTRY | 25 | Feb 8, 2023 | clinicaltrials |
| NCT03476239 | Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 121 | AmgenINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03856411 | A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC | completed | Phase 3 | 465 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT00354835 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma | completed | Phase 3 | 481 | Children's Oncology GroupNETWORK | 6 | Jan 31, 2023 | clinicaltrials |
| NCT02623309 | Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients | completed | Phase 3 | 108 | Institut Paoli-CalmettesOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03196986 | mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 517 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02420821 | A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)(IMmotion151) | completed | Phase 3 | 915 | Hoffmann-La RocheINDUSTRY | 21 | Jan 30, 2023 | clinicaltrials |
| NCT02438436 | Simo Decoction and Gum Chewing for Bowel Activity(SD/GC-HCC) | completed | Phase 3 | 180 | Guangxi Medical UniversityOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT02606461 | Selinexor in Advanced Liposarcoma(SEAL) | completed | Phase 2 / Phase 3 | 342 | Karyopharm Therapeutics IncINDUSTRY | 10 | Jan 23, 2023 | clinicaltrials |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein(REACH-2) | completed | Phase 3 | 399 | Eli Lilly and CompanyINDUSTRY | 20 | Jan 20, 2023 | clinicaltrials |
| NCT03294330 | SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer(SPYX) | completed | Phase 3 | 35 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT03682224 | Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients(BEMP) | completed | Phase 3 | 57 | Southern Illinois UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT00492856 | S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia | completed | Phase 3 | 105 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 10, 2023 | clinicaltrials |
| NCT01796002 | Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | completed | Phase 3 | 421 | The Lymphoma Academic Research OrganisationOTHER | 8 | Jan 10, 2023 | clinicaltrials |
| NCT02303119 | Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)(FLIRT) | completed | Phase 3 | 221 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02813785 | A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy(IMpower210) | completed | Phase 3 | 565 | Hoffmann-La RocheINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT03398655 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)(OVAL) | completed | Phase 3 | 408 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 5 | Jan 10, 2023 | clinicaltrials |
| NCT00473343 | Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma | completed | Phase 3 | 102 | Galderma R&DINDUSTRY | 1 | Jan 5, 2023 | clinicaltrials |
| NCT00075803 | Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) | completed | Phase 3 | 600 | Medical College of WisconsinOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT00075816 | Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) | completed | Phase 3 | 551 | Medical College of WisconsinOTHER | 2 | Jan 4, 2023 | clinicaltrials |
| NCT00406393 | Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | completed | Phase 3 | 304 | Medical College of WisconsinOTHER | 2 | Jan 4, 2023 | clinicaltrials |
| NCT02733068 | A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. | completed | Phase 3 | 12,000 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 0 | Dec 19, 2022 | clinicaltrials |
| NCT03353753 | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies(INVICTUS) | completed | Phase 3 | 129 | Deciphera Pharmaceuticals, LLCINDUSTRY | 13 | Nov 21, 2022 | clinicaltrials |
| NCT00115700 | Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma | completed | Phase 3 | 150 | Trans Tasman Radiation Oncology GroupOTHER | 3 | Nov 18, 2022 | clinicaltrials |
| NCT01568866 | Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients(ENDEAVOR) | completed | Phase 3 | 929 | AmgenINDUSTRY | 27 | Nov 14, 2022 | clinicaltrials |
| NCT03291977 | Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)(FLEGME) | completed | Phase 3 | 51 | Rennes University HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT01345019 | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma | completed | Phase 3 | 1,718 | AmgenINDUSTRY | 29 | Nov 8, 2022 | clinicaltrials |
| NCT01414608 | Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer | completed | Phase 3 | 926 | GOG FoundationNETWORK | 5 | Nov 7, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 27, 2023source: clinicaltrials